Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PREP | P48147 | 3/20 | 0.62 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.61 |
| ▸ | KLK7 | P49862 | 1/20 | 0.61 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.57 |
| ▸ | PRCP | P42785 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14893288 | 1.00 | TSHR (0.64) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL5764209 | 0.96 | FKBP1A (0.66) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL8280028 | 0.96 | FKBP1A (0.66) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL16272917 | 0.92 | FKBP1A (0.66) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL7326760 | 0.92 | FKBP1A (0.66) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL19360224 | 0.91 | TSHR (0.59) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL7414787 | 0.89 | TSHR (0.60) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL4724457 | 0.89 | PREP (0.67) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL630112 | 0.89 | PREP (0.67) | TSHRL3MBTL1KDM4ELMNAPREP | |
| SCHEMBL5525089 | 0.89 | PREP (0.67) | TSHRL3MBTL1KDM4ELMNAPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| US-10273239-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2771021-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTH WESTERN UNIV (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-28 | — | — | US | disclosed |
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
| US-8143249-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143249-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2011091407-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLP (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7625881-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625881-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | OPRL1, GRIN2A, GRM1 | TSHR 3202/4885L3MBTL1 2154/4885KDM4E 2150/4885 |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | TSHR 1558/4885L3MBTL1 4477/4885KDM4E 2649/4885 |
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | TSHR 214/4885L3MBTL1 1074/4885KDM4E 4139/4885 |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | TSHR 3329/4885L3MBTL1 2432/4885KDM4E 1522/4885 |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | TSHR 329/4885L3MBTL1 1685/4885KDM4E 4391/4885 |
| US-10273239-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | TSHR 1558/4885L3MBTL1 4477/4885KDM4E 2649/4885 |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | TSHR 1558/4885L3MBTL1 4477/4885KDM4E 2649/4885 |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | TSHR 3329/4885L3MBTL1 2432/4885KDM4E 1522/4885 |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | TSHR 3242/4885L3MBTL1 2493/4885KDM4E 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.